Breast Cancer
Conference Coverage
Continuing tamoxifen costs less, performs better in ER+ breast cancer
SAN DIEGO – How does adding 5 years of tamoxifen stack up to use of ovarian ablation plus an aromatase inhibitor in estrogen receptor-positive...
Conference Coverage
Intraoperative radiation looks good for DCIS
LAS VEGAS – Mammography and MRI may be sufficient to select appropriate patients with ductal carcinoma in situ.
Conference Coverage
Positive node risk defined for elderly breast cancer patients
LAS VEGAS – A new nomogram predicts nodal positivity in women aged 70 and older with hormone receptor–positive invasive breast cancer.
Conference Coverage
Forgo axillary dissection for single suspicious node on ultrasound
LAS VEGAS – Among 30 women with a primary tumor 2 cm or smaller and only one abnormal lymph node on axillary ultrasound, 22 (73%) had metastasis...
Conference Coverage
Omitting ALND in some breast cancer patients may be the right choice
PHILADELPHIA – A large MSKCC study may help surgeons decide on axillary lymph node dissection.
Conference Coverage
More early-stage cancer diagnosis since ACA implementation
Though the increase is small, cancer has been detected earlier and more often, indicating future improvements in care.
Conference Coverage
Three drug combinations represent next level for high-risk breast cancer
BRUSSELS – A three drug combination could reduce drug resistance and improve patient outcomes.
From the Journals
Genes may play role in breast cancer racial disparities
Researchers discover 142 genes differentially expressed between white and African American patients.
Conference Coverage
Decision to remove breast cancer metastases depends on location of lesions
LAS VEGAS – Surgery for a single brain metastasis improves survival with no extracranial disease and adjuvant WBR.
Conference Coverage
Androgen receptor screening not ready for triple-negative breast cancer
LAS VEGAS – Screening for androgen receptors is currently encouraged only in the context of clinical trials for triple-negative breast cancer.
Conference Coverage
Two new biomarkers show breast cancer validity
BRUSSELS – The two markers, high intratumor heterogeneity of estrogen-receptor density and pSTAT3 expression, are promising but need further...